~ Eligible individuals living with schizophrenia in Newfoundland will
now have access to a once-monthly treatment option ~
TORONTO, Feb. 27, 2014 /CNW/ - As of February 15, Newfoundland joins
seven other provinces in providing individuals living with
schizophrenia access to INVEGA SUSTENNA® (paliperidone palmitate), a long-acting monthly treatment option.
Available through the Newfoundland and Labrador Prescription Drug
Program (NLPDP), INVEGA SUSTENNA® is indicated for the treatment of schizophrenia in adults (18 years and
"I congratulate the Newfoundland government for its decision to add
INVEGA SUSTENNA® to the public drug formulary for the treatment of schizophrenia," says
Dr. Nizar Ladha*, a St. John's, Newfoundland psychiatrist. "I have seen
firsthand the benefits of a long-acting treatment in helping patients
stay adherent to medication, so that they can better manage their
condition and live healthier, more productive lives."
Newfoundland is the eighth province in Canada to include INVEGA SUSTENNA® on their public formularies, joining British Columbia, Alberta,
Saskatchewan, Ontario, Quebec, Nova Scotia and New Brunswick.
In June 2010, INVEGA SUSTENNA® was the first monthly long-acting injectable (LAI) atypical
anti-psychotic approved by Health Canada for the treatment of adults
with schizophrenia.1It is administered by a healthcare provider and offers patients an
alternative to daily oral medications. Treatment adherence is a major
barrier to the effective management of schizophrenia, and research has
shown that LAIs given at two to four week intervals2support medication monitoring3which can lead to improved adherence and may prevent relapses in
Individuals living with schizophrenia, their caregivers and health care
professionals in Newfoundland are encouraged to learn more about the
specific eligibility requirements that must be met for the
reimbursement of INVEGA SUSTENNA® by accessing the published list of medications covered by the
Newfoundland and Labrador Prescription Drug Program found at the
Schizophrenia in Canada
Schizophrenia is a chronic and serious condition that impairs a person's
ability to function to their potential when not treated.5 The condition affects one per cent of Canadians.6 It is a psychotic disorder that interferes with a person's ability to
think clearly, manage emotions, make decisions and relate to others.
The disease involves a loss of contact with reality, making it very
difficult for a person to distinguish between what is real and what is
not. Finding the right medication is one important aspect of symptom
management, but other services are also needed in order to promote
recovery. Rehabilitation strategies involving work, school and
relationship goals are also essential and need to be addressed in
creating a plan of care.
About Janssen Inc.
Janssen Inc. is one of the Janssen Pharmaceutical Companies, which are
dedicated to addressing and solving some of the most important unmet
medical needs in oncology, immunology, neuroscience, infectious
diseases and vaccines, and cardiovascular and metabolic diseases.
Driven by our commitment to patients, we bring innovative products,
services and solutions to people throughout the world. Please visit www.janssen.ca for more information.
All trademark rights used under license.
*Dr. Nizar Ladha was not compensated for any media work. He has been a
paid consultant to Janssen Inc.
1 INVEGA SUSTENNA® Product Monograph, Janssen Inc., December 9, 2013.
2 Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic
3 The Canadian Journal of Psychiatry. Long-Acting Injectable
Antipsychotics: Recommendations for Clinicians. Vol. 58, No 5,
Supplement 1. May 2013. Page 10S.
4 Lambert T. Practical management of schizophrenia: The role of
long-acting antipsychotics. Int Clin Psychopharmacol June 4, 2013 epub
ahead of print.
5 Schizophrenia Society of Canada. http://www.schizophrenia.ca/learn_more_about_schizophrenia.php#1.
6 Public Health Agency of Canada. http://www.phac-aspc.gc.ca/publicat/miic-mmac/chap_3-eng.php.
SOURCE: Janssen Inc.
For further information:
For more information, or to arrange an interview with Dr. Ladha, please contact: